[1]
|
Tian, J., Zhang, D., Yao, X., Huang, Y. and Lu, Q. (2023) Global Epidemiology of Systemic Lupus Erythematosus: A Comprehensive Systematic Analysis and Modelling Study. Annals of the Rheumatic Diseases, 82, 351-356.
https://doi.org/10.1136/ard-2022-223035
|
[2]
|
Barber, M.R.W., Drenkard, C., Falasinnu, T., et al. (2021) Global Epidemiology of Systemic Lupus Erythematosus. Nature Reviews Rheumatology, 17, 515-532. https://doi.org/10.1038/s41584-021-00668-1
|
[3]
|
Stojan, G. and Petri, M. (2018) Epidemiology of Systemic Lupus Erythematosus: An Update. Current Opinion in Rheumatology, 30, 144-150. https://doi.org/10.1097/BOR.0000000000000480
|
[4]
|
Jolly, M. (2005) How Does Quality of Life of Patients with Systemic Lupus Erythematosus Compare with That of Other Common Chronic Illnesses? The Journal of Rheumatology, 32, 1706-1708.
|
[5]
|
Hanly, J.G., O’Keeffe, A.G., Su, L., et al. (2016) The Frequency and Outcome of Lupus Nephritis: Results from an International Inception Cohort Study. Rheumatology, 55, 252-262. https://doi.org/10.1093/rheumatology/kev311
|
[6]
|
Jakes, R.W., Bae, S.C., Louthrenoo, W., et al. (2012) Systematic Review of the Epidemiology of Systemic Lupus Erythematosus in the Asia-Pacific Region: Prevalence, Incidence, Clini-cal Features, and Mortality. Arthritis Care & Research, 64, 159-168. https://doi.org/10.1002/acr.20683
|
[7]
|
Tektonidou, M.G., Dasgupta, A. and Ward, M.M. (2016) Risk of End-Stage Renal Disease in Patients with Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis & Rheumatology, 68, 1432-1441.
https://doi.org/10.1002/art.39594
|
[8]
|
Gasparotto, M., Gatto, M., Binda, V., Doria, A. and Moroni, G. (2020) Lu-pus Nephritis: Clinical Presentations and Outcomes in the 21st Century. Rheumatology, 59, v39-v51. https://doi.org/10.1093/rheumatology/keaa381
|
[9]
|
Almaani, S., Meara, A. and Rovin, B.H. (2017) Update on Lu-pus Nephritis. Clinical Journal of the American Society of Nephrology, 12, 825-835. https://doi.org/10.2215/CJN.05780616
|
[10]
|
Chen, Y.E., Korbet, S.M., Katz, R.S., Schwartz, M.M. and Lewis, E.J. (2008) Value of a Complete or Partial Remission in Severe Lupus Nephritis. Clinical Journal of the American Society of Nephrology, 3, 46-53.
https://doi.org/10.2215/CJN.03280807
|
[11]
|
Fanouriakis, A., Kostopoulou, M., Cheema, K., et al. (2020) 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) Recommendations for the Management of Lupus Nephritis. Annals of the Rheumatic Diseases, 79, 713-723.
https://doi.org/10.1136/annrheumdis-2020-216924
|
[12]
|
Rovin, B.H., Adler, S.G., Barratt, J., et al. (2021) Execu-tive Summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 100, 753-779. https://doi.org/10.1016/j.kint.2021.05.015
|
[13]
|
中华医学会风湿病学分会. 狼疮肾炎诊疗规范[J]. 中华内科杂志, 2021, 60(9): 784-790.
|
[14]
|
Wang, Z., Wang, Y., Zhu, R., et al. (2015) Long-Term Survival and Death Causes of Systemic Lupus Erythematosus in China: A Systemic Review of Observational Studies. Medicine, 94, e794.
https://doi.org/10.1097/MD.0000000000000794
|
[15]
|
Petri, M., Purvey, S., Fang, H. and Magder, L.S. (2012) Predictors of Organ Damage in Systemic Lupus Erythematosus: The Hopkins Lupus Cohort. Arthritis & Rheumatism, 64, 4021-4028. https://doi.org/10.1002/art.34672
|
[16]
|
Zahid, S., Mohamed, M.S., Wassif, H., et al. (2022) Analysis of Cardiovascular Complications during Delivery Admissions among Patients with Systemic Lupus Erythematosus, 2004-2019. JAMA Network Open, 5, e2243388.
https://doi.org/10.1001/jamanetworkopen.2022.43388
|
[17]
|
Takada, K., Illei, G.G. and Boumpas, D.T. (2001) Cy-clophosphamide for the Treatment of Systemic Lupus Erythematosus. Lupus, 10, 154-161. https://doi.org/10.1191/096120301671376017
|
[18]
|
Bruni, C., Shirai, Y., Kuwana, M. and Matucci-Cerinic, M. (2019) Cyclophosphamide: Similarities and Differences in the Treatment of SSc and SLE. Lupus, 28, 571-574. https://doi.org/10.1177/0961203319840433
|
[19]
|
Chen, Y., Sun, J., Zou, K., Yang, Y. and Liu, G. (2017) Treat-ment for Lupus Nephritis: An Overview of Systematic Reviews and Meta-Analyses. Rheumatology International, 37, 1089-1099. https://doi.org/10.1007/s00296-017-3733-2
|
[20]
|
Tunnicliffe, D.J., Palmer, S.C., Henderson, L., et al. (2018) Immunosuppressive Treatment for Proliferative Lupus Nephritis. Cochrane Database of Systematic Reviews, No. 6, Article No. CD002922.
https://doi.org/10.1002/14651858.CD002922.pub4
|
[21]
|
Dooley, M.A., Jayne, D., Ginzler, E.M., et al. (2011) Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. New England Journal of Medicine, 365, 1886-1895. https://doi.org/10.1056/NEJMoa1014460
|
[22]
|
Mok, C.C., Tong, K.H., To, C.H., Siu, Y.P. and Au, T.C. (2005) Tacrolimus for Induction Therapy of Diffuse Proliferative Lupus Nephritis: An Open-Labeled Pilot Study. Kidney International, 68, 813-817.
https://doi.org/10.1111/j.1523-1755.2005.00461.x
|
[23]
|
Zhou, T.B., Lin, S.J., Yang, S. and Lin, W.S. (2019) Effi-cacy and Safety of Tacrolimus in Induction Therapy of Patients with Lupus Nephritis. Drug Design, Development and Therapy, 13, 857-869.
https://doi.org/10.2147/DDDT.S189156
|
[24]
|
Liu, Z., Zhang, H., Liu, Z., et al. (2015) Multitarget Therapy for In-duction Treatment of Lupus Nephritis: A Randomized Trial. Annals of Internal Medicine, 162, 18-26. https://doi.org/10.7326/M14-1030
|
[25]
|
Zhang, H., Liu, Z., Zhou, M., et al. (2017) Multitarget Therapy for Mainte-nance Treatment of Lupus Nephritis. Journal of the American Society of Nephrology, 28, 3671-3678. https://doi.org/10.1681/ASN.2017030263
|
[26]
|
Ayoub, I., Nelson, J. and Rovin, B.H. (2018) Induction Therapy for Lupus Nephritis: The Highlights. Current Rheumatology Reports, 20, Article No. 60. https://doi.org/10.1007/s11926-018-0766-9
|
[27]
|
李鎛江, 肖友文, 董建华, 何玲, 潘红霞. 环磷酰胺联合激素诱导治疗狼疮性肾炎的临床效果[J]. 中外医学研究, 2020, 18(23): 28-30.
|
[28]
|
Alforaih, N., Whittall-Garcia, L. and Touma, Z. (2022) A Review of Lupus Nephritis. The Journal of Applied Laboratory Medicine, 7, 1450-1467. https://doi.org/10.1093/jalm/jfac036
|
[29]
|
Marín-Rosales, M., Palafox-Sánchez, C.A., Franco-Topete, R.A., et al. (2023) Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis. Jour-nal of Clinical Medicine, 12, Article No. 71.
https://doi.org/10.3390/jcm12010071
|
[30]
|
Yap, D.Y.H. and Chan, T.M. (2019) B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments. Inter-national Journal of Molecular Sciences, 20, Article No. 6231. https://doi.org/10.3390/ijms20246231
|
[31]
|
Swaak, A.J.G., Huysen, V., Nossent, J.C. and Smeenk, R.J.T. (1990) Antinuclear Antibody Profiles in Relation to Specific Dis-ease Manifestations of Systemic Lupus Erythematosus. Clinical Rheumatology, 9, 82-95.
https://doi.org/10.1007/BF02205555
|
[32]
|
Frodlund, M., Wetterö, J., Dahle, C., et al. (2020) Longitudinal An-ti-Nuclear Antibody (ANA) Seroconversion in Systemic Lupus Erythematosus: A Prospective Study of Swedish Cases with Recent-Onset Disease. Clinical & Experimental Immunology, 199, 245-254. https://doi.org/10.1111/cei.13402
|
[33]
|
Enocsson, H., Sjöwall, C., Wirestam, L., et al. (2015) Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity. The Journal of Rheu-matology, 42, 817-825.
https://doi.org/10.3899/jrheum.140677
|
[34]
|
Chan, O.T.M., Hannum, L.G., Haberman, A.M., Madaio, M.P. and Shlomchik, M.J. (1999) A Novel Mouse with B Cells but Lacking Serum Antibody Reveals an Antibody-independent Role for B Cells in Murine Lupus. The Journal of Experimental Medicine, 189, 1639-1648. https://doi.org/10.1084/jem.189.10.1639
|
[35]
|
张莹莹, 王世颖, 束庆, 等. 靶向B淋巴细胞治疗系统性红斑狼疮的生物制剂: 贝利尤单抗与泰它西普[J]. 中南药学, 2022, 20(10): 2356-2362.
|
[36]
|
Anolik, J.H., Campbell, D., Felgar, R.E., et al. (2003) The Relationship of FcγRIIIa Genotype to Degree of B Cell Depletion by Rituximab in the Treatment of Systemic Lupus Erythematosus. Arthritis & Rheumatism, 48, 455-459.
https://doi.org/10.1002/art.10764
|
[37]
|
Faustini, F., Sippl, N., Stålesen, R., et al. (2022) Rituximab in Systemic Lu-pus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Im-munogenicity. Frontiers in Immunology, 13, Article 826152. https://doi.org/10.3389/fimmu.2022.826152
|
[38]
|
Salazar-Camarena, D.C., Ortiz-Lazareno, P.C., Cruz, A., et al. (2016) Association of BAFF, APRIL Serum Levels, BAFF-R, TACI and BCMA Expression on Peripheral B-Cell Sub-sets with Clinical Manifestations in Systemic Lupus Erythematosus. Lupus, 25, 582-592. https://doi.org/10.1177/0961203315608254
|
[39]
|
Vital, E.M., Dass, S., Buch, M.H., et al. (2011) B Cell Bi-omarkers of Rituximab Responses in Systemic Lupus Erythematosus. Arthritis & Rheumatism, 63, 3038-3047. https://doi.org/10.1002/art.30466
|
[40]
|
Rönnblom, L. and Leonard, D. (2019) Interferon Pathway in SLE: One Key to Unlocking the Mystery of the Disease. Lupus Science & Medicine, 6, e000270. https://doi.org/10.1136/lupus-2018-000270
|
[41]
|
Yazdany, J. and Davis, J. (2004) The Role of CD40 Ligand in Systemic Lupus Erythematosus. Lupus, 13, 377-380.
https://doi.org/10.1191/0961203304lu1030oa
|
[42]
|
Comte, D., Karampetsou, M.P. and Tsokos, G.C. (2015) T Cells as a Therapeutic Target in SLE. Lupus, 24, 351-363.
https://doi.org/10.1177/0961203314556139
|
[43]
|
Robles-Carrillo, L., Meyer, T., Hatfield, M., et al. (2010) An-ti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice. The Journal of Immunology, 185, 1577-1583.
https://doi.org/10.4049/jimmunol.0903888
|
[44]
|
Furie, R.A., Bruce, I.N., Dörner, T., et al. (2021) Phase 2, Ran-domized, Placebo-Controlled Trial of Dapirolizumab Pegol in Patients with Moderate-to-Severe Active Systemic Lupus Erythematosus. Rheumatology, 60, 5397-5407.
https://doi.org/10.1093/rheumatology/keab381
|
[45]
|
Jacobi, A.M., Mei, H., Hoyer, B.F., et al. (2010) HLA-DRhigh/CD27high Plasmablasts Indicate Active Disease in Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 69, 305-308.
https://doi.org/10.1136/ard.2008.096495
|
[46]
|
Cole, S., Walsh, A., Yin, X., et al. (2018) Integrative Analysis Re-veals CD38 as a Therapeutic Target for Plasma Cell-Rich Pre-Disease and Established Rheumatoid Arthritis and System-ic Lupus Erythematosus. Arthritis Research & Therapy, 20, Article No. 85. https://doi.org/10.1186/s13075-018-1578-z
|
[47]
|
Bag-Ozbek, A. and Hui-Yuen, J.S. (2021) Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Therapeutics and Clinical Risk Management, 17, 39-54. https://doi.org/10.2147/TCRM.S252592
|
[48]
|
Shrestha, S., Budhathoki, P., Adhikari, Y., et al. (2021) Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis. Cureus, 13, e20440. https://doi.org/10.7759/cureus.20440
|
[49]
|
Parodis, I., Gatto, M. and Sjöwall, C. (2022) B Cells in Systemic Lupus Erythematosus: Targets of New Therapies and Surveillance Tools. Frontiers in Medicine, 9, Article 952304. https://doi.org/10.3389/fmed.2022.952304
|
[50]
|
Vincent, F.B., Saulep-Easton, D., Figgett, W.A., Fairfax, K.A. and Mackay, F. (2013) The BAFF/APRIL System: Emerging Functions beyond B Cell Biology and Autoimmunity. Cytokine & Growth Factor Reviews, 24, 203-215.
https://doi.org/10.1016/j.cytogfr.2013.04.003
|
[51]
|
Vincent, F.B., Kandane-Rathnayake, R., Koelmeyer, R., et al. (2019) Analysis of Serum B Cell-Activating Factor From the Tumor Necrosis Factor Family (BAFF) and Its Soluble Receptors in Systemic Lupus Erythematosus. Clinical & Translational Immunology, 8, e1047. https://doi.org/10.1002/cti2.1047
|
[52]
|
Schwarting, A., Relle, M., Meineck, M., et al. (2018) Renal Tubular Epithe-lial Cell-Derived BAFF Expression Mediates Kidney Damage and Correlates with Activity of Proliferative Lupus Ne-phritis in Mouse and Men. Lupus, 27, 243-256. https://doi.org/10.1177/0961203317717083
|
[53]
|
Furie, R., Rovin, B.H., Houssiau, F., et al. (2020) Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New Eng-land Journal of Medicine, 383, 1117-1128. https://doi.org/10.1056/NEJMoa2001180
|
[54]
|
Navarra, S.V., Guzmán, R.M., Gallacher, A.E., et al. (2011) Efficacy and Safety of Belimumab in Patients with Active Systemic Lupus Erythe-matosus: A Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 377, 721-731.
https://doi.org/10.1016/S0140-6736(10)61354-2
|
[55]
|
Furie, R., Petri, M., Zamani, O., et al. (2011) A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stimulator, in Patients with Systemic Lupus Erythematosus. Arthritis & Rheumatism, 63, 3918-3930. https://doi.org/10.1002/art.30613
|
[56]
|
Stohl, W., Hiepe, F., Latinis, K.M., et al. (2012) Belimumab Reduces Auto-antibodies, Normalizes Low Complement Levels, and Reduces Select B Cell Populations in Patients with Systemic Lupus Erythematosus. Arthritis & Rheumatism, 64, 2328-2337. https://doi.org/10.1002/art.34400
|
[57]
|
Stohl, W., Schwarting, A., Okada, M., et al. (2017) Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythema-tosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis & Rheumatology, 69, 1016-1027. https://doi.org/10.1002/art.40049
|
[58]
|
Zhang, F., Bae, S.C., Bass, D., et al. (2018) A Pivotal Phase III, Randomised, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Erythematosus Located in China, Japan and South Korea. Annals of the Rheumatic Diseases, 77, 355-363. https://doi.org/10.1136/annrheumdis-2017-211631
|
[59]
|
Li, M., Wang, Y., Zhao, J., et al. (2021) Chinese SLE Treatment and Research Group (CSTAR) Registry 2009-2019: Major Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus. Rheumatology and Immunology Research, 2, 43-47. https://doi.org/10.2478/rir-2021-0001
|
[60]
|
Urowitz, M.B., Gladman, D.D., Ibanez, D., et al. (2012) Evolution of Disease Burden over Five Years in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis Care & Re-search, 64, 132-137.
https://doi.org/10.1002/acr.20648
|
[61]
|
Collins, C.E., Cortes-Hernández, J., Garcia, M.A., et al. (2020) Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatology and Therapy, 7, 949-965. https://doi.org/10.1007/s40744-020-00243-2
|
[62]
|
Urowitz, M.B., Ohsfeldt, R.L., Wielage, R.C., et al. (2019) Or-gan Damage in Patients Treated with Belimumab versus Standard of Care: A Propensity Score-Matched Comparative Analysis. Annals of the Rheumatic Diseases, 78, 372-379.
https://doi.org/10.1136/annrheumdis-2018-214043
|
[63]
|
Bruce, I.N., Urowitz, M., Van Vollenhoven, R., et al. (2016) Long-Term Organ Damage Accrual and Safety in Patients with SLE Treated with Belimumab Plus Standard of Care. Lupus, 25, 699-709.
https://doi.org/10.1177/0961203315625119
|
[64]
|
Cassia, M., Alberici, F., Gallieni, M. and Jayne, D. (2017) Lupus Nephritis and B-Cell Targeting Therapy. Expert Review of Clinical Immunology, 13, 951-962. https://doi.org/10.1080/1744666X.2017.1366855
|
[65]
|
Atisha-Fregoso, Y., Malkiel, S., Harris, K.M., et al. (2021) Phase II Randomized Trial of Rituximab plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis & Rheumatology, 73, 121-131.
https://doi.org/10.1002/art.41466
|
[66]
|
Cancro, M.P., D’Cruz, D.P. and Khamashta, M.A. (2009) The Role of B Lymphocyte Stimulator (BLyS) in Systemic Lupus Erythematosus. The Journal of Clinical Investigation, 119, 1066-1073. https://doi.org/10.1172/JCI38010
|
[67]
|
Samy, E., Wax, S., Huard, B., Hess, H. and Schneider, P. (2017) Targeting BAFF and APRIL in Systemic Lupus Erythematosus and Other Antibody-Associated Diseases. International Reviews of Immunology, 36, 3-19.
https://doi.org/10.1080/08830185.2016.1276903
|
[68]
|
Steiger, S., Ehreiser, L., Anders, J. and Anders, H.-J. (2022) Biological Drugs for Systemic Lupus Erythematosus or Active Lupus Nephritis and Rates of Infectious Complications. Evidence from Large Clinical Trials. Frontiers in Immunology, 13, Article 999704. https://doi.org/10.3389/fimmu.2022.999704
|